Biohaven (BHVN) Capital Expenditures (2021 - 2026)
Biohaven (BHVN) posted Capital Expenditures of $8000.0 for Q4 2025, down 38.46% sequentially from $13000.0 in Q3 2025, and down 83.67% YoY from $49000.0 in Q4 2024.
Biohaven (BHVN) Capital Expenditures (2021 - 2026) Analysis & Trends
Biohaven has reported Capital Expenditures for 5 years, with the latest figure at $8000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 83.67% year-over-year to $8000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $254000.0 (down 93.76% YoY) and the FY2025 annual result came in at $715000.0, down 82.34% from the prior year.
- Capital Expenditures eased to $8000.0 in Q4 2025 per BHVN's latest filing, from $13000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $4.5 million in Q3 2022 and troughed at $8000.0 in Q4 2025.
- A 5-year average of $863823.5 and a median of $470000.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures surged 395.63% in 2024, then plunged 97.87% in 2025.
- Over 5 years, Capital Expenditures stood at $799000.0 in 2021, then sank by 62.45% to $300000.0 in 2022, then jumped by 56.67% to $470000.0 in 2023, then plunged by 89.57% to $49000.0 in 2024, then sank by 83.67% to $8000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $8000.0, $13000.0, and $233000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | 454,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 454,000.00 |
| Jun 30, 2026 | 454,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 233,000.00 |
| Jun 30, 2025 | 233,000.00 |
| Mar 31, 2025 | 461,000.00 |
| Mar 31, 2025 | 461,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 611,000.00 |
| Sep 30, 2024 | 611,000.00 |
| Jun 30, 2024 | 2.95 Mn |
| Jun 30, 2024 | 2.95 Mn |
| Mar 31, 2024 | 440,000.00 |
| Mar 31, 2024 | 440,000.00 |
| Dec 31, 2023 | 470,000.00 |
| Dec 31, 2023 | 470,000.00 |